Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Automated Cell Culture System Market size was valued at USD 8.21 billion in 2024 and is set to exceed USD 37.09 billion by 2037, expanding at over 12.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of automated cell culture system is evaluated at USD 9.91 billion.
The growth of the market can primarily be attributed to the increasing stem cell research & development owing to the higher prevalence of related diseases. For instance, in 2019, more than 8 million people were found to be suffering from Parkinson’s disease.
A cell culture system is a process that consists particular instrument to conduct steps to grow and maintain cell culture. In a cell culture system, an environment is constituted to with controlled conditions, separated from the natural environment. Global automated cell culture market trends such as, escalating research and development activities and spiking prevalence of cancer are expected to influence the growth of the market over the forecast period. According to World Health Organization, cancer is designated as the leading cause of death, which caused about 10 million deaths in 2020, it is also stated by the similar source that in every 6 deaths, 1 is caused by cancer.
Automated Cell Culture System Sector: Growth Drivers and Challenges
Growth Drivers
-
Significant Demand in the Treatment of Skin Problems - In 2022, over 6 million Americans were found to be living with psoriasis while about 200 million were across the globe.
The cell culture system puts regenerative medicines in use for patients practically. Cells are used by regenerative medicines in the form of therapeutic agents which are required for the medical treatment associated with repairing, rebuilding, and making the human body function properly. Hence such a significant utilization is estimated to propel the market growth over the forecast period.
- Rising Cases of Non-Communicable Diseases - Data published by the World Health Organization showed that nearly 41 million individuals die due to non-communicable diseases every year.
- Higher Prevalence of Infectious Diseases - The annual rate of death caused by infectious diseases is estimated to be more than 15 million a year.
- Growing Healthcare Expenditure Across the Globe - As per the statistics provided by the World Bank, global health expenditure was estimated to reach USD 1,121.9 per capita.
- Increasing Number of Clinical Trials - As of 2021, the number of clinical trials is estimated to be nearly 0.4 million in about 200 countries.
Challenges
-
Lack of Skilled Medical Professionals
-
Lack of Required Technology to Develop the Cell Culture System
- Requirement for Higher Initial Investment
Automated Cell Culture System Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.3% |
|
Base Year Market Size (2024) |
USD 8.21 billion |
|
Forecast Year Market Size (2037) |
USD 37.09 billion |
|
Regional Scope |
|
Automated Cell Culture System Segmentation
End-user (Academic Institutes, Biotech Company)
The global automated cell culture system market is segmented and analyzed for demand and supply by end-user into academic institutes, biotech company, and research organization, out of which, the biotech company segment is projected to witness noteworthy growth over the forecast period. The growth of the segment can be accounted to the rising activities of research and development across the globe. For instance, the biotech industry was valued at approximately USD 450 billion in 2025.
Mode of Delivery (Topical Application, Aerial Diffusion, Direct Inhalation)
On the other, on the basis of mode of delivery, automated cell culture system market is segmented into topical application, aerial diffusion, and direct inhalation. Out of all these, the topical application will garner the highest market share of 41% by 2037. The rising technological advancements along with the huge investments made in the healthcare sector is expected to bring lucrative opportunities for the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Line Culture |
|
|
By Application |
|
|
By Mode of Delivery |
|
|
By End-User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Automated Cell Culture System Industry - Regional Synopsis
North America industry is predicted to dominate majority revenue share of 41% by 2037, attributed to rising investment in research and development in the region. The growth of the market is attributed to rising investment in research and development in the region. The National Cancer Institute (NIC) published statistics showing that the NCI budget to make funding for research for cancer reached USD 6440.4 million in 2020. Additionally, the higher prevalence of chronic diseases and the presence of major key players in the region is further expected to propel the growth of the market over the forecast period. Furthermore, the Europe region is also estimated to provide a lucrative opportunity for the market to grow exponentially.
Companies Dominating the Automated Cell Culture System Landscape
- Hitachi Power Solutions Co, Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Lonza Group Ltd.
- Thermo Fisher Scientific Company
- Cell Culture Company, LLC
- Sartorius AG
- Becton, Dickinson and Company
- Hamilton Company
- Merck Group
- F. Hoffmann-La Roche AG
- Novartis AG
Recent Developments
-
Hitachi Power Solutions Co., Ltd. to launch FineSAT7, a scanning acoustic tomograph with higher image quality. this scanning acoustic tomograph is used to detect particular defects in the body with help of transmissive and reflective properties of ultrasonic waves.
-
Becton, Dickinson and Company to start the enrollment for the first-in-human trial for sirolimus drug-coated balloons (DCB). The company is conducting these trials to improve the treatment option for peripheral arterial diseases.
- Report ID: 4262
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
